Conference Report

New Drug Targets and Advances in Therapeutics for the Treatment of Viral Hepatitis

Source: CCO Independent Conference Coverage of the HEP DART 2005: Frontiers in Drug Development for Viral Hepatitis*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

New Drug Targets and Advances in Therapeutics for the Treatment of Viral Hepatitis


Program Director: Gary L. Davis, MD

Faculty:

  • Gary L. Davis, MD
  • Robert G. Gish, MD

CME CREDIT INFORMATION

Release Date: 03/20/06

Expiration Date: 03/19/07


Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the role of viral targets in the drug development and discovery process
  • Identify the next generation of inhibitors of viral hepatitis
  • Assess the impact of resistance and treatment failure in the drug development and discovery process
  • Identify the consequences of coinfection with HIV in the management of patients

Topics covered include:

  • Overview
  • In Vitro Models of Hepatitis C Virus Infection
  • HCV Interactions With the Host Cell
  • Tailoring HCV Therapy
  • Overview of Current HCV Targets
  • Progress on New HCV Targets: NS2 and NS5A
  • Hepatitis C Virus-Cell Entry
  • Valopicitabine (NM-283) Plus Peginterferon for the Treatment of Chronic Hepatitis C
  • VX-950 for HCV Treatment
  • SCH503034 for HCV Treatment
  • Novel Potent Inhibitors of the HCV NS3/4 Protease
  • Acylated PreS Peptides for Acute and Chronic Hepatitis B Treatment
  • Novel Mouse Models for HBV Therapeutics
  • Role of Neutralizing Antibodies in HCV
  • Development of Prophylactic and Therapeutic Vaccines Against HCV
  • Using Protein Structure to Design Antiviral Agents
  • Targeting TLRs for HCV Treatment
  • Regulation of TLR Expression in Chronic Hepatitis B
  • Development of Therapeutic siRNAs for the Treatment of Viral Hepatitis
  • Overview of Hepatitis B Treatment
  • Pradefovir
  • Correlation Between 24- and 48-Week Virologic Response to HBV Treatment
  • Evolution of HBV Drug Resistance
  • Impact of Transplant Practice on HBV Drug Resistance
  • HIV/HCV Coinfection and Management
  • HIV/HBV Coinfection and Management
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.